(Q47830170)

6 February 2018

review article

1 reference

title

New thrombin inhibitors in cardiovascular disease. (English)

1 reference

6 February 2018

main subject

cardiovascular disease

1 reference

Ripka WC

1

1 reference

6 February 2018

publication date

1 August 1997

1 reference

6 February 2018

Current Opinion in Chemical Biology

published in

1 reference

6 February 2018

volume

1

1 reference

6 February 2018

issue

2

1 reference

6 February 2018

page(s)

242-253

1 reference

6 February 2018

Thrombin receptor function and cardiovascular disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

New anticoagulant strategies. Current status and future potential

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Late-fibrin(ogen) fragment E modulates human alpha-thrombin specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Oral anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Current and future perspectives on antithrombotic therapy of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Thrombin inhibitors A new generation of antithrombotics

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

First-pass elimination of a peptidomimetic thrombin inhibitor is due to carrier-mediated uptake by the liver. Interaction with bile acid transport systems

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

The clot thickens: clues provided by thrombin structure.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Glu-192----Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Electrostatic interactions in hirudin-thrombin binding.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Nonpolar interactions of thrombin and its inhibitors at the fibrinogen recognition exosite: thermodynamic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an alpha-keto-amide transition-state mimetic

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Crystal structures of thrombin with thiazole-containing inhibitors: probes of the S1' binding site

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Crystallographic determination of the structures of human alpha-thrombin complexed with BMS-186282 and BMS-189090

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Design, synthesis, and evolution of a novel, selective, and orally bioavailable class of thrombin inhibitors: P1-argininal derivatives incorporating P3-P4 lactam sulfonamide moieties

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Potent and selective thrombin inhibitors incorporating the constrained arginine mimic l-3-piperidyl(N-guanidino)alanine at P1.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Crystal structure of a peptidyl pyridinium methyl ketone inhibitor with thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Mechanism of action of thrombin on fibrinogen. Kinetic evidence for involvement of aspartic acid at position P10

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Structure of the hirulog 3-thrombin complex and nature of the S' subsites of substrates and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Kinetics of the inhibition of thrombin by hirudin.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Rational design of true hirudin mimetics: synthesis and characterization of multisite-directed alpha-thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Kinetics of human thrombin inhibition by two novel peptide inhibitors (Hirunorm IV and Hirunorm V)

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human alpha-thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Bothrojaracin: a potent two-site-directed thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Selection of single-stranded DNA molecules that bind and inhibit human thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

A novel oligodeoxynucleotide inhibitor of thrombin. II. Pharmacokinetics in the cynomolgus monkey.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980016-6

7 January 2021

10.1016/S1367-5931(97)80016-6

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018